A Study of LY2875358 in Participants With Advanced Cancer
Status:
Completed
Trial end date:
2016-10-26
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine a recommended Phase 2 dose range of LY2875358
that may be safely administered to participants with advanced cancer. In Part A and Part A2
of this study, escalating doses of LY2875358 as monotherapy and in combination with erlotinib
will be evaluated for safety and tolerability, respectively. Part B is a dose-confirmation
segment for LY2875358 therapy in 5 different types of cancer: nonsquamous non-small cell lung
cancer (NSCLC), castrate resistant prostate cancer (CRPC) with bone metastases, renal cell
carcinoma (RCC), hepatocellular carcinoma (HCC), or uveal melanoma with liver metastases, and
for LY2875358 in combination with trametinib in participants with uveal melanoma with liver
metastases.